Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 26;18(11):1184–1195. doi: 10.1038/s41589-022-01116-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a, Structure of C3A. b, C3A fluorescence polarization (FP) competition with A26-Fl against cyclophilins with S2 pocket lysines. c, Cyclophilin prolyl-isomerase inhibition screen of C3A, showing potency and selectivity for CypE. d, Mass spectroscopy trace of CypE incubated with C3A and reduced with sodium cyanoborohydride. C3A shows an adduct consistent with CypE + amine–H₂O (+806 Da), the result of iminoboronate formation followed by reductive amination. The mass of CypE is 20,708 Da, The CypE preparation also included N-terminal gluconoylation. e, Prolyl-isomerase inhibition by C3A against CypE S2 pocket lysine to alanine mutants. For the FP assay, the y-axis is normalized to internal control wells containing A26-Fl only (100%) and A26-Fl with cyclophilin (0%). Values reflect mean of three technical replicates and error bars reflect s.d. of individual assays at one dose. For the prolyl-isomerase assay in c and the CypE wild-type dose–response curve in e, IC₅₀ values reflect mean ± s.d. of four independent replicates (each comprising three technical replicates). Graph shows a representative single independent replicate (Independent replicate 3 is shown, containing three technical replicates) with data points and error bars reflecting mean ± s.d. of individual assays at one dose. Further independent replicates are shown in Supplementary Fig. 28b. For the prolyl-isomerase assay in e, IC₅₀ values for the CypE mutants reflect mean ± s.e.m. of three technical replicates, while data points and error bars reflect mean ± s.d. of individual assays at one dose.

Source data